ATE397091T1 - Verfahren und zusammensetzungen zur vorhersage der irinotecantoxizität - Google Patents

Verfahren und zusammensetzungen zur vorhersage der irinotecantoxizität

Info

Publication number
ATE397091T1
ATE397091T1 AT04753702T AT04753702T ATE397091T1 AT E397091 T1 ATE397091 T1 AT E397091T1 AT 04753702 T AT04753702 T AT 04753702T AT 04753702 T AT04753702 T AT 04753702T AT E397091 T1 ATE397091 T1 AT E397091T1
Authority
AT
Austria
Prior art keywords
compositions
methods
irinotecantoxicity
predicting
ironotecan
Prior art date
Application number
AT04753702T
Other languages
English (en)
Inventor
Mark Ratain
Federico Innocenti
Rienzo Anna Di
Carrie Grimsley
Original Assignee
Univ Chicago
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Univ Chicago filed Critical Univ Chicago
Application granted granted Critical
Publication of ATE397091T1 publication Critical patent/ATE397091T1/de

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
    • C12Q1/6876—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes
    • C12Q1/6883—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/48—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving transferase
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00—Oligonucleotides characterized by their use
    • C12Q2600/156—Polymorphic or mutational markers

Landscapes

  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Zoology (AREA)
  • Wood Science & Technology (AREA)
  • Engineering & Computer Science (AREA)
  • Genetics & Genomics (AREA)
  • Analytical Chemistry (AREA)
  • Microbiology (AREA)
  • Biochemistry (AREA)
  • Biotechnology (AREA)
  • Molecular Biology (AREA)
  • Biophysics (AREA)
  • Physics & Mathematics (AREA)
  • General Health & Medical Sciences (AREA)
  • Immunology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Engineering & Computer Science (AREA)
  • Pathology (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
  • Agricultural Chemicals And Associated Chemicals (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
AT04753702T 2003-05-30 2004-05-28 Verfahren und zusammensetzungen zur vorhersage der irinotecantoxizität ATE397091T1 (de)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US47482603P 2003-05-30 2003-05-30

Publications (1)

Publication Number Publication Date
ATE397091T1 true ATE397091T1 (de) 2008-06-15

Family

ID=33511633

Family Applications (1)

Application Number Title Priority Date Filing Date
AT04753702T ATE397091T1 (de) 2003-05-30 2004-05-28 Verfahren und zusammensetzungen zur vorhersage der irinotecantoxizität

Country Status (8)

Country Link
US (1) US7807350B2 (de)
EP (1) EP1629111B1 (de)
JP (1) JP2006526412A (de)
AT (1) ATE397091T1 (de)
CA (1) CA2527320A1 (de)
DE (1) DE602004014135D1 (de)
ES (1) ES2308208T3 (de)
WO (1) WO2004108954A1 (de)

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2007055261A1 (ja) * 2005-11-10 2007-05-18 The New Industry Research Organization Ｕｇｔ１ａ１遺伝子多型の検査法
KR101153058B1 (ko) 2006-11-30 2012-06-04 아크레이 가부시키가이샤 Ｕｇｔ1ａ1 유전자 증폭용 프라이머 셋트, 그것을 포함하는 ｕｇｔ1ａ1 유전자 증폭용 시약 및 그 용도
CN107858429A (zh) * 2017-11-10 2018-03-30 广州金域医学检验集团股份有限公司 用于检测ugt1a1基因启动子区ta重复多态性的扩增引物、方法及应用

Family Cites Families (23)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1994022846A1 (en) 1993-03-30 1994-10-13 Pfizer Inc. Compounds enhancing antitumor activity of other cytotoxic agents
EP0721328A4 (de) 1993-09-27 1997-09-17 Smithkline Beecham Corp Camptothecin-formulierungen
US5786344A (en) 1994-07-05 1998-07-28 Arch Development Corporation Camptothecin drug combinations and methods with reduced side effects
US5919816A (en) 1994-11-14 1999-07-06 Bionumerik Pharmaceuticals, Inc. Formulations and methods of reducing toxicity of antineoplastic agents
US5972614A (en) 1995-12-06 1999-10-26 Genaissance Pharmaceuticals Genome anthologies for harvesting gene variants
ATE305052T1 (de) 1996-03-01 2005-10-15 Univ Dundee Drogen untersuchungssystem
WO1997044466A1 (en) 1996-05-17 1997-11-27 Endorecherche, Inc. Characterization and use of an isolated uridine diphospho-glucuronosyltransferase
DE19744676A1 (de) 1997-10-10 1999-04-15 Forschungszentrum Borstel Zent Kombinationspräparate für die Therapie von Tumoren
EP1084271A2 (de) 1998-05-07 2001-03-21 Axys Pharmaceuticals, Inc. Typisierung des humanen udp-glucuronosyltransferase 1 (ugt1) genes
US6448003B1 (en) 1998-06-10 2002-09-10 Dna Sciences Laboratories, Inc. Genotyping the human phenol sulfotransferbase 2 gene STP2
US6407117B1 (en) 1998-06-18 2002-06-18 The George Washington University Method of administering camptothecin compounds for the treatment of cancer with reduced side effects
US6319678B1 (en) 1998-06-26 2001-11-20 Panvera Corporation Process for glucuronidation screening
US6586175B1 (en) 1998-07-28 2003-07-01 Dna Sciences Laboratories, Inc. Genotyping the human UDP-glucuronosyltransferase 2B7 (UGT2B7) gene
US6395481B1 (en) 1999-02-16 2002-05-28 Arch Development Corp. Methods for detection of promoter polymorphism in a UGT gene promoter
WO2001079230A2 (en) 2000-04-18 2001-10-25 Genaissance Pharmaceuticals, Inc. Haplotypes of the ugt1a1 gene
EP1325152A2 (de) 2000-07-14 2003-07-09 F. Hoffmann-La Roche Ag Methode zur detektion der veranlagung für hepatotoxizität
WO2002057410A2 (en) 2000-11-28 2002-07-25 Dna Sciences Laboratories, Inc. Genetic typing of human genes and related materials and methods
WO2002048400A1 (en) 2000-12-12 2002-06-20 Nagoya Industrial Science Research Institute Method of estimating risk of the expression of side effect caused by the administration of compound metabolized, either per se or as its metabolic intermediate, by ugt1a1 enzyme
DE10100238A1 (de) 2001-01-05 2002-08-22 Hannover Med Hochschule Verfahren zur Vorhersage des Gefährdungspotentials für Karzinomerkrankungen und entzündliche Darmerkrankungen und zugehörige Tests
US20030099960A1 (en) 2001-01-26 2003-05-29 The University Of Chicago Compositions and methods for optimizing UGT2B7 substrate dosings and for predicting UGT2B7 substrate toxicity
JP2005501840A (ja) 2001-07-23 2005-01-20 エピダウロス・バイオテクノロジー・アクチェンゲゼルシャフト 癌の改良された治療のための手段および方法
JP4096037B2 (ja) 2002-08-12 2008-06-04 国立大学法人滋賀医科大学 グルクロン酸転移酵素遺伝子の変異解析による薬剤代謝活性の予測方法
US20040203034A1 (en) 2003-01-03 2004-10-14 The University Of Chicago Optimization of cancer treatment with irinotecan

Also Published As

Publication number Publication date
US20070197574A1 (en) 2007-08-23
US7807350B2 (en) 2010-10-05
ES2308208T3 (es) 2008-12-01
CA2527320A1 (en) 2004-12-16
DE602004014135D1 (de) 2008-07-10
JP2006526412A (ja) 2006-11-24
WO2004108954A1 (en) 2004-12-16
EP1629111A1 (de) 2006-03-01
EP1629111B1 (de) 2008-05-28

Similar Documents

Publication Publication Date Title
EP2230319A3 (de) Genexpressionsmarker für Brustkrebsprognose
WO2006093507A3 (en) Methods and systems for predicting cancer outcome
DE602004019812D1 (de) Marker für neuromyelitis optica
CY1111246T1 (el) Προληψη και θεραπεια επαγομενης απο φλεγμονη και/ή ανοσοδιαμεσολαβουμενης οστικης απωλειας
ATE335722T1 (de) Benzoylsulfonamide und sulfonylbenzamidine zur verwendung als antitumor-mittel
ATE427499T1 (de) Zusammensetzungen und verfahren zur quantifizierung von serumglykoproteinen
AU3084802A (en) Inflammatory markers as tools in the detection and prevention of diabetes mellitus and as tools to aid in the selection of agents to be used for the prevention and treatment of diabetes
ZA200710910B (en) Methods for the assessment of risk of developing lung cancer using analysis of genetic polymorphisms
TW200636076A (en) Method for measuring resistance or sensitivity to docetaxel
EP1725111A4 (de) Verfahren und zusammensetzungen zur metastasenhemmung
WO2005004814A3 (en) Sirt1 and genetic disorders
NO20015814D0 (no) Metallkompleksforbindelser
WO2006079101A3 (en) Associations using genotypes and phenotypes
EP2249155A3 (de) Krebsmarker
DE602004014135D1 (de) Verfahren und zusammensetzungen zur vorhersage der irinotecantoxizität
ATE456801T1 (de) Verfahren zur messung immunsuppressiver tacrolimus-, sirolimus- und cyclosporin-a- komplexe in einer blutprobe
DK2327792T3 (da) Fremgangsmåder og sammensætninger til påvisning af autoimmunsygdomme
MXPA05008793A (es) Metodos para la prediccion de posibilidad de suicidio durante el tratamiento.
ATE451476T1 (de) Zusammensetzungen und methoden zur bestimmung des mikrosatelliten instabilitäts (msi) status
WO2005072151A3 (en) Apoe genetic markers associated with age of onset of alzheimer's disease
WO2006099259A3 (en) Novel missense mutations and single nucleotide polymorphisms in the rabphillin-3a-like gene and uses thereof
WO2004070012A3 (en) Cell-killing molecules and methods of use thereof
DE10290016D2 (de) Verfahren zur Vorhersage des Gefährdungspotentials für Karzinomerkrankungen und entzündliche Darmerkrankungen und zugehörige Tests
DE602004031533D1 (de) Verbessertes verfahren zur atp-amplifikation und verwendung davon
WO2004096021A3 (en) Global analysis of transposable elements as molecular markers of cancer

Legal Events

Date Code Title Description
RER Ceased as to paragraph 5 lit. 3 law introducing patent treaties